

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

IN THIS ISSUE (starts on next page)

In Brief: Two New Seasonal Influenza Vaccines p 12

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions, Site Licenses, Reprints](#)
or call customer service at: 800-211-2769**

FORWARDING OR COPYING IS A VIOLATION OF US AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 145 Huguenot Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 55 (Issue 1409)
February 4, 2013

www.medicalletter.org
[Take CME Exams](#)

IN BRIEF

Two New Seasonal Influenza Vaccines

Two new trivalent influenza vaccines, *Flucelvax* (Novartis) and *Flublok* (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥ 18 years old (*Flucelvax*) and 18-49 years old (*Flublok*). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.

Table 1. New Influenza Vaccines

Vaccine	FDA- Approved Age	Route/ Formulation	Cost ¹
<i>Flublok</i> (Protein Sciences)	18-49 years	IM/0.5 mL single-dose vial ²	\$30.00
<i>Flucelvax</i> (Novartis)	≥ 18 years	IM/0.5 mL syringe ²	18.25

1. Approximate cost of a single dose according to the manufacturer.
2. Sold in boxes of 10.

Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is grown in canine kidney cell culture instead of chicken eggs. In an unpublished study summarized in the package insert comparing *Flucelvax* with placebo in more than 11,000 patients during the 2007-2008 season, the new vaccine was effective in preventing about 84% of cases of influenza due to matching strains and was about 70% effective when non-matching strains were included.

Flublok is produced without use of influenza virus or chicken eggs; a gene that encodes for hemagglutinin antigen (HA) is introduced into baculovirus, a virus that infects insect cells, and the replicating baculovirus produces large amounts of HA. In a study in about 4,600 adults conducted during one influenza season, *Flublok* was about 45% effective compared to placebo in preventing culture-confirmed influenza despite a significant

antigenic mismatch between the vaccine and circulating viruses (96% of circulating strains did not match the vaccine). It was 75% effective in preventing illness caused by matching strains.¹

Both *Flublok* and *Flucelvax* provide protection against the same strains as the other vaccines available for the 2012-2013 influenza season.²

1. JJ Treanor et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. *Vaccine* 2011; 29:7733.
2. Influenza vaccine 2012-2013. *Med Lett Drugs Ther* 2012; 54:77.

The Medical Letter®
On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Corinne Z. Morrison, Pharm.D.
CONSULTING EDITORS: Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.
CONTRIBUTING EDITORS:
Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons
Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School
Eric J. Epstein, M.D., Albert Einstein College of Medicine
Jane P. Gagliardi, M.D., M.H.S., F.A.C.P. Duke University School of Medicine
Jules Hirsch, M.D., Rockefeller University
David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre
Richard B. Kim, M.D., University of Western Ontario
Hans Meinertz, M.D., University Hospital, Copenhagen
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
Dan M. Roden, M.D., Vanderbilt University School of Medicine
Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D., New York University School of Medicine
Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weil Medical College of Cornell University
SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard
ASSOCIATE EDITOR: Cynthia Macapagal Covey
EDITORIAL FELLOW: Jennifer Y. Lin, M.D., Harvard Medical School
MANAGING EDITOR: Susie Wong
ASSISTANT MANAGING EDITOR: Liz Donohue
PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona
FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski
DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino
VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy
Founded in 1959 by
Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or donations. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address: The Medical Letter, Inc. 145 Huguenot St. Ste. 312 New Rochelle, NY 10801-7537	Subscriptions (US): 1 year - \$98; 2 years - \$189; 3 years - \$279. \$49.00 per year for students, interns, residents and fellows in the US and Canada.
Customer Service: Call: 800-211-2769 or 914-235-0500 Fax: 914-632-1733 Web Site: www.medicalletter.org E-mail: custserv@medicalletter.org	E-mail site license inquiries to: info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.
Permissions: To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org	

Copyright 2013. ISSN 1523-2859

